Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP-1 drugs while facing potential legal challenges.

HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $31.86 which represents a slight increase of $0.32 or 1.01% from the prior close of $31.54. The stock opened at $31.9 and ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...

Hims evaluates the nutrition of easy-prep slow cooker recipes designed to get your tailgate party off to a fun and healthy ...

Super Bowl ads have hit $8 million each, as advertisers shell out big bucks to get their products in the spotlight. That’s a ...

Hers shares information about the average weight for women in the U.S., what women believe the ideal weight is, and the ...

Hims & Hers Health, Inc. (HIMS) closed the latest trading day at $31.86, indicating a +1.01% change from the previous session's end. The stock exceeded the S&P 500, which registered a loss of 0.47% ...

VC, a venture firm led by Palantir founder Joe Lonsdale, is seeking nearly $1 billion for its sixth fund, according to a ...

In a paper published in Nature Communications, researchers at the Industrial Sustainable Chemistry group of the University of ...

“I spend far less than I used to on food,” Hunter Stoler, 24, told The Post, revealing he’s dropped 45 lbs. — and slashed a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.